Clinical trials: Low Risk Prostate Cancer
Metastatic Prostate Cancer
Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer
This study is being done to determine the safety, biodistribution, and radiation dosimetry of 18F-DCFPyL, and to detect prostate cancer by visual analysis.
- Trial name
- NCT02151760
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostatic Neoplasms, Prostate Cancer
Focal Therapy for Prostate Cancer
Prostate cancer is the most common solid organ cancer among men and is the second leading cause of cancer death. In 2013 about 238,590 men will be diagnosed with prostate cancer and 29,720 men will die of the cancer.
- Trial name
- NCT01802307
- Testing
- Brachytherapy
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Low-Risk Prostate Cancer
Biological Markers and Advanced Imaging for Prostate Cancer Progression in Active Surveillance
This study aims to identify patients with low-risk prostate cancer (ISUP Grade Group 1) eligible for active surveillance who are at higher risk of upgrading to ISUP Grade Group 2 or higher at confirmatory biopsy one year after…
- Trial name
- PSMA-AS (NCT06866041)
- Testing
- mpMRI-targeted confirmatory biopsy
- Where
- Italy
- Volunteers
- 74 people
- Sponsor
- Università Vita-Salute San Raffaele
Prostate Cancer
LDR Brachytherapy Versus SBRT for Low and Intermediate Risk Prostate Cancer Patients
The aim of this trial is to find out if there are any differences in the profiles of acute and late adverse effects among men with low and intermediate risk prostate cancer treated either with low dose-rate brachytherapy or…
- Trial name
- BRAVEROBO (NCT02895854)
- Testing
- Hypofractionated RT 5 x 7,25 Gy, LDR-brachytherapy with I125 seeds
- Where
- Finland
- Volunteers
- 44 people
- Sponsor
- Kuopio University Hospital
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Prostate Adenocarcinoma
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread…
- Trial name
- NCT05050084
- Testing
- Bicalutamide, Buserelin, Darolutamide
- Where
- 576 sites in United States, Canada
- Volunteers
- 2,050 people
- Sponsor
- NRG Oncology
Prostate Cancer
Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR Brachytherapy
Optimal non surgical treatment of prostate cancer requires dose escalation which is frequently provided by adding a brachytherapy "boost" to a short course of external beam radiotherapy.
- Trial name
- BrachyQOL (NCT01936883)
- Testing
- HDR, LDR
- Where
- Canada
- Volunteers
- 195 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer
The purpose of this study is to evaluate the effects of Noni extract in men diagnosed with very low risk or low risk prostate cancer
- Trial name
- NCT02648919
- Testing
- Noni extract
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Hawaii
Prostate Cancer, Localized Prostate Carcinoma
MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer
The goal of this clinical trial is to determine the safety of stereotactic body radiation therapy (SBRT) microboost technique in patients with low to intermediate risk prostate cancer.
- Trial name
- MIDAS (NCT07644598)
- Testing
- Microboost SBRT, Whole gland de-escalation 30 Gy, Whole gland de-escalation 35 Gy
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Georgetown University
Prostate Cancer
Stereotactic Body Radiotherapy vs Intensity-modulated Radiotherapy in Prostate Cancer
The primary goal of this phase II study is to compare the change of EPIC HRQOL scores (1-year minus baseline) between SBRT and IMRT.
- Trial name
- NCT02339701
- Testing
- IMRT, SBRT
- Where
- Hong Kong
- Volunteers
- 68 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer Adenocarcinoma in Situ
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
This research is being done to see if an investigational prostate cancer vaccine, called GVAX, can safely be given together with a single intravenous injection of a drug called cyclophosphamide to men that will undergo surgery to…
- Trial name
- NCT01696877
- Testing
- degarelix acetate, Cyclophosphamide, GVAX
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostatic Neoplasms, Prostate Cancer
Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer
This trial uses a ultra high-resolution ultrasound system and specialized transducer, intended for use in prostate imaging. The system's image resolution is significantly better than the standard of care, due to its higher…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Cancer of the Prostate
- Trial name
- NCT02079025
- Testing
- High-resolution ultrasound guided prostate biopsy, Standard ultrasound guided prostate biopsy
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,676 people
- Sponsor
- Exact Imaging
Prostate Carcinoma, Erectile Function
Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers
This prospective randomized controlled trial (RCT) is designed to provide high level evidence on the efficacy of Low-intensity Extracorporeal Shock Wave Therapy (Li-ESWT) in the treatment of post-Robot-Assisted (RA) Radical…
- Conditions
- Prostate Carcinoma, Erectile Function, Genito Urinary Cancer
- Trial name
- RCT_LiESWT (NCT06717711)
- Testing
- Low-intensity Extracorporeal Shock Wave Therapy (LiESWT), PDE5 inhibitor (tadalafil)
- Where
- 2 sites in Italy
- Volunteers
- 158 people
- Sponsor
- Regina Elena Cancer Institute
Prostate Cancer Recurrent
Sipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate Cancer
This is a single-center, randomized, open-label study to assess the feasibility of a low-protein diet intervention in patients with metastatic castrate-resistant prostate cancer (CRPC) who are receiving treatment with…
- Trial name
- NCT03329742
- Testing
- Low protein diet, Control protein diet
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Indiana University
Prostate Cancer
Study In Urology Practices Looking At Impact Of OncotypeDX GPS Test On Men Choosing And Remaining On Active Surveillance
Genomic Health's OncotypeDX® Prostate Cancer Assay is a commercially available laboratory test that measures the activity of certain genes in prostate cancer.
- Trial name
- NCT03502213
- Volunteers
- 489 people
- Sponsor
- Genomic Health®, Inc.
Prostate Cancer
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer
Prostate cancer patients diagnosed with a biochemical recurrence and limited metastases are conventionally treated with androgen deprivation therapy.
- Trial name
- NCT01558427
- Testing
- Surveillance, Salvage treatment
- Where
- Belgium
- Volunteers
- 62 people
- Sponsor
- University Hospital, Ghent
Prostate Cancer
Stereotactic Ablative Radiation Therapy for Prostate Cancer
This single arm trial will investigate a novel way to plan and deliver SABR for prostate cancer. Prostate-directed SABR will be high-dose SABR (40 Gy in 5 fractions) with central sparing of the urethra and peripheral sparing of…
- Trial name
- SUPR-SABR (NCT05668351)
- Testing
- SUPR-SABR treatment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Medical University of South Carolina
Breast Cancer, Colorectal Cancer
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
RATIONALE: Dalteparin may be effective in inhibiting the growth of blood vessels in tumors, decreasing the risk of metastatic cancer, preventing the formation of blood clots, and improving quality of life in treating patients…
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00003674
- Testing
- dalteparin, standard therapy
- Where
- 20 sites in United States, Canada
- Volunteers
- 141 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Evaluation of Four Treatment Modalities in Prostate Cancer With Low or "Early Intermediate" Risk
4arms preference based Study to compare four therapy options in prostate cancer with low or early intermediate risk
- Trial name
- PREFERE (NCT01717677)
- Testing
- radical prostatectomy, percutaneous radiation therapy, permanent seed implantation
- Where
- 2 sites in Germany
- Volunteers
- 457 people
- Sponsor
- Association of Urologic Oncology (AUO)
Prostate Cancer, Low and Intermediate Risk Prostate Cancer
MRI Guided Focal Laser Ablation of Prostate Cancer
This clinical research study is designed to determine the ability of in bore MRI guided Focal Laser Ablation (MRgFLA) in patients with early stage carcinoma of prostate.
- Trial name
- MRgFLA (NCT03650595)
- Testing
- The TRANBERGCLS|Thermal Therapy
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- University Health Network, Toronto